Source link : https://www.newshealth.biz/health-news/ocrelizumab-trial-fills-research-gap-for-black-hispanic-ms-patients/
DENVER — Among Black/African American and Hispanic/Latino patients with relapsing multiple sclerosis (MS) in the phase IV CHIMES trial, half achieved a combined measure for no evidence of disease activity (NEDA) with ocrelizumab (Ocrevus). After 48 weeks of treatment with ocrelizumab among 182 participants, 50.5% achieved the primary efficacy endpoint of NEDA-3, which measures a […]
Author : News Health
Publish date : 2024-04-18 20:30:02
Copyright for syndicated content belongs to the linked Source.